Top

Published in:

Open Access 01-05-2020 | Gastric Cancer | Original Paper

Identification of novel biomarkers, MUC5AC, MUC1, KRT7, GAPDH, CD44 for gastric cancer

Author: Jie Yang

Published in: Medical Oncology | Issue 5/2020

Abstract

Gastric cancer (GC) is one of the most common malignant tumors in the world, and it is also the third largest cause of cancer-related death in the world. As far as we know, no biomarker has been widely accepted for early diagnosis and prognosis prediction of gastric cancer. The purpose of this study is to find potential biomarkers to predict the prognosis of GC. The gene expression profiles of GSE2685 were downloaded from GEO database. Morpheus was used to calculate the differentially expressed genes (DEGs) between primary advanced gastric cancer tissues and noncancerous gastric tissues. The gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes pathway (KEGG) enrichment analyses were performed, and protein–protein interaction (PPI) network of DEGs was constructed. Kaplan–Meier Plotter was used to determine the overall survival (OS) outcomes of UC5AC, MUC1, KRT7, GAPDH, CD44, and GEPIA was used to determine the Pearson correlation analysis. In total, 710 DEGs were identified in GC, including 396 upregulated genes and 314 downregulated genes. GO enrichment revealed that they were mainly enriched in binding, catalytic activity, cellular process and cell. KEGG pathway revealed that they were mainly enriched in metabolic pathways, pathways in cancer and PI3K-Akt signaling pathway. MUC5AC, MUC1, KRT7, GAPDH, CD44 were identified from the PPI network. MUC5AC, MUC1, KRT7, GAPDH, CD44 were demonstrated to have prognostic value for patients with GC. MUC5AC, MUC1 exhibited low expression levels in GC tissues, KRT7, GAPDH, CD44 presented high expression levels in GC tissues. In particular, KRT7 is hardly expressed in normal gastric tissues. MUC5AC and MUC1 were negatively correlated with GAPDH, CD44, respectively; and GAPDH was positively correlated with CD44 and KRT7, respectively. Moreover. MUC5AC, MUC1, KRT7, GAPDH, and CD44 are not only related to GC but also to apoptosis pathway. Results from the present study suggested that MUC5AC, MUC1, KRT7, GAPDH, CD44 may represent novel prognostic biomarkers for GC.

Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008;9(3):279–87. https://doi.org/10.1016/S1470-2045(08)70072-X.CrossRefPubMed

Zhang G, Li J, Li S, Wang Y. Exploring spatial trends and influencing factors for gastric cancer based on Bayesian statistics: a case study of Shanxi, China. Int J Environ Res Public Health. 2018. https://doi.org/10.3390/ijerph15091824.CrossRefPubMedPubMedCentral

Ning S, Wei W, Li J, Hou B, Zhong J, Xie Y, et al. Clinical significance and diagnostic capacity of serum TK1, CEA, CA 19–9 and CA 72–4 levels in gastric and colorectal cancer patients. J Cancer. 2018;9(3):494–501. https://doi.org/10.7150/jca.21562.CrossRefPubMedPubMedCentral

Bluvshtein GA, Lysenko VG, Zakharova NB, Kitaev IV. Tumor markers p53, sFAS, FASL, CEA and CA 19–9 in evaluating the effectiveness of surgical and pharmaco nutritional treatment of patients with gastric cancer. Eksperimental'naia i Klinicheskaia Gastroenterologiia. 2012;2:41–9.

Kim DH, Oh SJ, Oh CA, Choi MG, Noh JH, Sohn TS, et al. The relationships between perioperative CEA, CA 19–9, and CA 72–4 and recurrence in gastric cancer patients after curative radical gastrectomy. J Surg Oncol. 2011;104(6):585–91. https://doi.org/10.1002/jso.21919.CrossRefPubMed

Tian SB, Yu JC, Kang WM, Ma ZQ, Ye X, Cao ZJ, et al. Combined detection of CEA, CA 19–9, CA 242 and CA 50 in the diagnosis and prognosis of resectable gastric cancer. Asian Pac J Cancer Prev. 2014;15(15):6295–300. https://doi.org/10.7314/apjcp.2014.15.15.6295.CrossRefPubMed

Dilege E, Mihmanli M, Demir U, Ozer K, Bostanci O, Kaya C, et al. Prognostic value of preoperative CEA and CA 19–9 levels in resectable gastric cancer. Hepatogastroenterology. 2010;57(99–100):674–7.PubMed

Zhang LX, Wei ZJ, Xu AM, Zang JH. Can the neutrophil-lymphocyte ratio and platelet-lymphocyte ratio be beneficial in predicting lymph node metastasis and promising prognostic markers of gastric cancer patients? Tumor maker retrospective study. Int J Surg. 2018;56:320–7. https://doi.org/10.1016/j.ijsu.2018.06.037.CrossRefPubMed

Yesseyeva G, Aikemu B, Hong H, Yu C, Dong F, Sun J, et al. Prefoldin subunits (PFDN1-6) serve as poor prognostic markers in gastric cancer. Biosci Rep. 2020. https://doi.org/10.1042/BSR20192712.CrossRefPubMedPubMedCentral

10.

Ahmed A. Prevalence of Her3 in gastric cancer and its association with molecular prognostic markers: a Saudi cohort based study. Libyan J Med. 2019;14(1):1574532. https://doi.org/10.1080/19932820.2019.1574532.CrossRefPubMedPubMedCentral

11.

Feng F, Sun L, Liu Z, Liu S, Zheng G, Xu G, et al. Prognostic values of normal preoperative serum cancer markers for gastric cancer. Oncotarget. 2016;7(36):58459–69. https://doi.org/10.18632/oncotarget.11248.CrossRefPubMedPubMedCentral

12.

Liu X, Wu Z, Lin E, Li W, Chen Y, Sun X, et al. Systemic prognostic score and nomogram based on inflammatory, nutritional and tumor markers predict cancer-specific survival in stage II-III gastric cancer patients with adjuvant chemotherapy. Clin Nutr. 2019;38(4):1853–60. https://doi.org/10.1016/j.clnu.2018.07.015.CrossRefPubMed

13.

Lopes LO, Maues JH, Ferreira-Fernandes H, Yoshioka FK, Junior SCS, Santos AR, et al. New prognostic markers revealed by RNA-Seq transcriptome analysis after MYC silencing in a metastatic gastric cancer cell line. Oncotarget. 2019;10(56):5768–79. https://doi.org/10.18632/oncotarget.27208.CrossRefPubMedPubMedCentral

14.

Shen Y, Zhang J, Fu Z, Zhang B, Chen M, Ling X, et al. Gene microarray analysis of the circular RNAs expression profile in human gastric cancer. Oncol Lett. 2018;15(6):9965–72. https://doi.org/10.3892/ol.2018.8590.CrossRefPubMedPubMedCentral

15.

Takeno A, Takemasa I, Seno S, Yamasaki M, Motoori M, Miyata H, et al. Gene expression profile prospectively predicts peritoneal relapse after curative surgery of gastric cancer. Ann Surg Oncol. 2010;17(4):1033–42. https://doi.org/10.1245/s10434-009-0854-1.CrossRefPubMed

16.

Wang T, Xu Y, Hou P. Identifying novel biomarkers of gastric cancer through integration analysis of single nucleotide polymorphisms and gene expression profile. Int J Biol Markers. 2015;30(3):e321–e326326. https://doi.org/10.5301/jbm.5000145.CrossRefPubMed

17.

Xu ZY, Chen JS, Shu YQ. Gene expression profile towards the prediction of patient survival of gastric cancer. Biomed Pharmacother. 2010;64(2):133–9. https://doi.org/10.1016/j.biopha.2009.06.021.CrossRefPubMed

18.

Yu CD, Xu SH, Mou HZ, Jiang ZM, Zhu CH, Liu XL. Gene expression profile differences in gastric cancer, pericancerous epithelium and normal gastric mucosa by gene chip. World J Gastroenterol. 2005;11(16):2390–7. https://doi.org/10.3748/wjg.v11.i16.2390.CrossRefPubMedPubMedCentral

19.

Hippo Y, Taniguchi H, Tsutsumi S, Machida N, Chong JM, Fukayama M, et al. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res. 2002;62(1):233–40.PubMed

20.

Giraldi L, Michelazzo MB, Arzani D, Persiani R, Pastorino R, Boccia S. MUC1, MUC5AC, and MUC6 polymorphisms, Helicobacter pylori infection, and gastric cancer: a systematic review and meta-analysis. Eur J Cancer Prev. 2018;27(4):323–30. https://doi.org/10.1097/CEJ.0000000000000348.CrossRefPubMed

21.

Wang C, Wang J, Liu Y, Guo X, Zhang C. MUC5AC upstream complex repetitive region length polymorphisms are associated with susceptibility and clinical stage of gastric cancer. PLoS ONE. 2014;9(6):e98327. https://doi.org/10.1371/journal.pone.0098327.CrossRefPubMedPubMedCentral

22.

Park KK, Yang SI, Seo KW, Yoon KY, Lee SH, Jang HK, et al. Correlations of human epithelial growth factor receptor 2 overexpression with MUC2, MUC5AC, MUC6, p53, and clinicopathological characteristics in gastric cancer patients with curative resection. Gastroenterol Res Pract. 2015;2015:946359. https://doi.org/10.1155/2015/946359.CrossRefPubMedPubMedCentral

23.

Mori Y, Kataoka H, Miura Y, Kawaguchi M, Kubota E, Ogasawara N, et al. Subcellular localization of ATBF1 regulates MUC5AC transcription in gastric cancer. Int J Cancer. 2007;121(2):241–7. https://doi.org/10.1002/ijc.22654.CrossRefPubMed

24.

Xu Y, Zhang L, Hu G. Potential application of alternatively glycosylated serum MUC1 and MUC5AC in gastric cancer diagnosis. Biologicals. 2009;37(1):18–25. https://doi.org/10.1016/j.biologicals.2008.08.002.CrossRefPubMed

25.

Shi D, Qiu XM, Yan XJ. The changes in MUC5AC expression in gastric cancer before and after Helicobacter pylori eradication. Clin Res Hepatol Gastroenterol. 2014;38(2):235–40. https://doi.org/10.1016/j.clinre.2013.06.008.CrossRefPubMed

26.

Shi D, Qiu XM, Bao YF. Effects of Helicobacter pylori infection on MUC5AC protein expression in gastric cancer. Future Oncol. 2013;9(1):115–20. https://doi.org/10.2217/fon.12.172.CrossRefPubMed

27.

Kim SM, Kwon CH, Shin N, Park DY, Moon HJ, Kim GH, et al. Decreased Muc5AC expression is associated with poor prognosis in gastric cancer. Int J Cancer. 2014;134(1):114–24. https://doi.org/10.1002/ijc.28345.CrossRefPubMed

28.

Zhang CT, He KC, Pan F, Li Y, Wu J. Prognostic value of Muc5AC in gastric cancer: a meta-analysis. World J Gastroenterol. 2015;21(36):10453–60. https://doi.org/10.3748/wjg.v21.i36.10453.CrossRefPubMedPubMedCentral

29.

Zhou CJ, Zhang LW, Gao F, Zhang B, Wang Y, Chen DF, et al. Association analysis of common genetic variations in MUC5AC gene with the risk of non-cardia gastric cancer in a Chinese population. Asian Pac J Cancer Prev. 2014;15(10):4207–10. https://doi.org/10.7314/apjcp.2014.15.10.4207.CrossRefPubMed

30.

Jiang K, Liu H, Xie D, Xiao Q. Differentially expressed genes ASPN, COL1A1, FN1, VCAN and MUC5AC are potential prognostic biomarkers for gastric cancer. Oncol Lett. 2019;17(3):3191–202. https://doi.org/10.3892/ol.2019.9952.CrossRefPubMedPubMedCentral

31.

Liu BL, Qin JJ, Shen WQ, Liu C, Yang XY, Zhang XN, et al. FOXA1 promotes proliferation, migration and invasion by transcriptional activating KRT7 in human gastric cancer cells. J Biol Regul Homeost Agents. 2019;33(4):1041–50.PubMed

32.

Huang B, Song JH, Cheng Y, Abraham JM, Ibrahim S, Sun Z, et al. Long non-coding antisense RNA KRT7-AS is activated in gastric cancers and supports cancer cell progression by increasing KRT7 expression. Oncogene. 2016;35(37):4927–36. https://doi.org/10.1038/onc.2016.25.CrossRefPubMedPubMedCentral

33.

Butera G, Mullappilly N, Masetto F, Palmieri M, Scupoli MT, Pacchiana R, et al. Regulation of autophagy by nuclear GAPDH and its aggregates in cancer and neurodegenerative disorders. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20092062.CrossRefPubMedPubMedCentral

34.

Butera G, Pacchiana R, Mullappilly N, Margiotta M, Bruno S, Conti P, et al. Mutant p53 prevents GAPDH nuclear translocation in pancreatic cancer cells favoring glycolysis and 2-deoxyglucose sensitivity. Biochim Biophys Acta Mol Cell Res. 2018;1865(12):1914–23. https://doi.org/10.1016/j.bbamcr.2018.10.005.CrossRefPubMed

35.

Caradec J, Sirab N, Revaud D, Keumeugni C, Loric S. Is GAPDH a relevant housekeeping gene for normalisation in colorectal cancer experiments? Br J Cancer. 2010;103(9):1475–6. https://doi.org/10.1038/sj.bjc.6605851.CrossRefPubMedPubMedCentral

36.

Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Vossen JA, Tchernyshyov I, et al. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. Anticancer Res. 2009;29(12):4909–18.PubMedPubMedCentral

37.

Hansen CN, Ketabi Z, Rosenstierne MW, Palle C, Boesen HC, Norrild B. Expression of CPEB, GAPDH and U6snRNA in cervical and ovarian tissue during cancer development. APMIS. 2009;117(1):53–9. https://doi.org/10.1111/j.1600-0463.2008.00015.x.CrossRefPubMed

38.

Hjerpe E, Egyhazi Brage S, Carlson J, Frostvik Stolt M, Schedvins K, Johansson H, et al. Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer. BMC Clin Pathol. 2013;13(1):30. https://doi.org/10.1186/1472-6890-13-30.CrossRefPubMedPubMedCentral

39.

Jung DW, Kim WH, Seo S, Oh E, Yim SH, Ha HH, et al. Chemical targeting of GAPDH moonlighting function in cancer cells reveals its role in tubulin regulation. Chem Biol. 2014;21(11):1533–45. https://doi.org/10.1016/j.chembiol.2014.08.017.CrossRefPubMed

40.

Zhong XY, Yuan XM, Xu YY, Yin M, Yan WW, Zou SW, et al. CARM1 methylates GAPDH to regulate glucose metabolism and is suppressed in liver cancer. Cell Rep. 2018;24(12):3207–23. https://doi.org/10.1016/j.celrep.2018.08.066.CrossRefPubMed

41.

Kim SH, Park WS, Lee SJ, Choi MK, Yeon SM, Joo JN, et al. The quantified level of circulating prostate stem cell antigen mRNA relative to GAPDH level is a clinically significant indictor for predicting biochemical recurrence in prostate cancer patients after radical prostatectomy. Biomed Res Int. 2015;2015:292454. https://doi.org/10.1155/2015/292454.CrossRefPubMedPubMedCentral

42.

Kunjithapatham R, Ganapathy-Kanniappan S. GAPDH with NAD(+)-binding site mutation competitively inhibits the wild-type and affects glucose metabolism in cancer. Biochim Biophys Acta Gen Subj. 2018;1862(12):2555–633. https://doi.org/10.1016/j.bbagen.2018.08.001.CrossRefPubMed

43.

Nicholls C, Pinto AR, Li H, Li L, Wang L, Simpson R, et al. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) induces cancer cell senescence by interacting with telomerase RNA component. Proc Natl Acad Sci USA. 2012;109(33):13308–13. https://doi.org/10.1073/pnas.1206672109.CrossRefPubMed

44.

Soltany-Rezaee-Rad M, Mottaghi-Dastjerdi N, Setayesh N, Roshandel G, Ebrahimifard F, Sepehrizadeh Z. Overexpression of FOXO3, MYD88, and GAPDH identified by suppression subtractive hybridization in esophageal cancer is associated with autophagy. Gastroenterol Res Pract. 2014;2014:185035. https://doi.org/10.1155/2014/185035.CrossRefPubMedPubMedCentral

45.

Zhang JY, Zhang F, Hong CQ, Giuliano AE, Cui XJ, Zhou GJ, et al. Critical protein GAPDH and its regulatory mechanisms in cancer cells. Cancer Biol Med. 2015;12(1):10–22. https://doi.org/10.7497/j.issn.2095-3941.2014.0019.CrossRefPubMedPubMedCentral

46.

Kawada M, Inoue H, Ohba S, Yoshida J, Masuda T, Yamasaki M, et al. Stromal cells positively and negatively modulate the growth of cancer cells: stimulation via the PGE2-TNFalpha-IL-6 pathway and inhibition via secreted GAPDH-E-cadherin interaction. PLoS ONE. 2015;10(3):e0119415. https://doi.org/10.1371/journal.pone.0119415.CrossRefPubMedPubMedCentral

47.

Tongtawee T, Wattanawongdon W, Simawaranon T, Kaewpitoon S, Kaengpenkae S, Jintabanditwong N, et al. Expression of cancer stem cell marker CD44 and its polymorphisms in patients with chronic gastritis, precancerous gastric lesion, and gastric cancer: a cross-sectional multicenter study in Thailand. Biomed Res Int. 2017;2017:4384823. https://doi.org/10.1155/2017/4384823.CrossRefPubMedPubMedCentral

48.

Szczepanik A, Sierzega M, Drabik G, Pituch-Noworolska A, Kolodziejczyk P, Zembala M. CD44(+) cytokeratin-positive tumor cells in blood and bone marrow are associated with poor prognosis of patients with gastric cancer. Gastric Cancer. 2019;22(2):264–72. https://doi.org/10.1007/s10120-018-0858-2.CrossRefPubMed

49.

Sun M, Zhou W, Zhang YY, Wang DL, Wu XL. CD44(+) gastric cancer cells with stemness properties are chemoradioresistant and highly invasive. Oncol Lett. 2013;5(6):1793–8. https://doi.org/10.3892/ol.2013.1272.CrossRefPubMedPubMedCentral

50.

Senel F, Kokenek Unal TD, Karaman H, Inanc M, Aytekin A. Prognostic value of cancer stem cell markers CD44 and ALDH1/2 in gastric cancer cases. Asian Pac J Cancer Prev. 2017;18(9):2527–31. https://doi.org/10.22034/APJCP.2017.18.9.2527.CrossRefPubMedPubMedCentral

51.

Zavros Y. Initiation and maintenance of gastric cancer: a focus on CD44 variant isoforms and cancer stem cells. Cell Mol Gastroenterol Hepatol. 2017;4(1):55–63. https://doi.org/10.1016/j.jcmgh.2017.03.003.CrossRefPubMedPubMedCentral

52.

Yamaguchi A, Saito M, Gio T, Iida A, Takeuchi K, Hirose K, et al. Expression of CD44 variant exons 8–10 in gastric cancer. Jpn J Cancer Res. 1995;86(12):1166–71. https://doi.org/10.1111/j.1349-7006.1995.tb03310.x.CrossRefPubMedPubMedCentral

53.

Setala L, Lipponen P, Tammi R, Tammi M, Eskelinen M, Alhava E, et al. Expression of CD44 and its variant isoform v3 has no prognostic value in gastric cancer. Histopathology. 2001;38(1):13–20. https://doi.org/10.1046/j.1365-2559.2001.01038.x.CrossRefPubMed

54.

Go SI, Ko GH, Lee WS, Kim RB, Lee JH, Jeong SH, et al. CD44 variant 9 serves as a poor prognostic marker in early gastric cancer, but not in advanced gastric cancer. Cancer Res Treat. 2016;48(1):142–52. https://doi.org/10.4143/crt.2014.227.CrossRefPubMed

55.

Go SI, Ko GH, Lee WS, Lee JH, Jeong SH, Lee YJ, et al. The use of CD44 variant 9 and Ki-67 combination can predicts prognosis better than their single use in early gastric cancer. Cancer Res Treat. 2019;51(4):1411–9. https://doi.org/10.4143/crt.2018.663.CrossRefPubMedPubMedCentral

56.

Yong CS, Ou Yang CM, Chou YH, Liao CS, Lee CW, Lee CC. CD44/CD24 expression in recurrent gastric cancer: a retrospective analysis. BMC Gastroenterol. 2012;12:95. https://doi.org/10.1186/1471-230X-12-95.CrossRefPubMedPubMedCentral

57.

Yoon C, Park DJ, Schmidt B, Thomas NJ, Lee HJ, Kim TS, et al. CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin Cancer Res. 2014;20(15):3974–88. https://doi.org/10.1158/1078-0432.CCR-14-0011.CrossRefPubMedPubMedCentral

58.

Yu D, Shin HS, Choi G, Lee YC. Proteomic analysis of CD44(+) and CD44(-) gastric cancer cells. Mol Cell Biochem. 2014;396(1–2):213–20. https://doi.org/10.1007/s11010-014-2156-6.CrossRefPubMed

59.

Zhang C, Li C, He F, Cai Y, Yang H. Identification of CD44+CD24+ gastric cancer stem cells. J Cancer Res Clin Oncol. 2011;137(11):1679–86. https://doi.org/10.1007/s00432-011-1038-5.CrossRefPubMed

60.

Zhang D, Jia H, Wang Y, Li WM, Hou YC, Yin SW, et al. A CD44 specific peptide developed by phage display for targeting gastric cancer. Biotechnol Lett. 2015;37(11):2311–20. https://doi.org/10.1007/s10529-015-1896-z.CrossRefPubMed

61.

Zeng JF, Ma XQ, Wang LP, Wang W. MicroRNA-145 exerts tumor-suppressive and chemo-resistance lowering effects by targeting CD44 in gastric cancer. World J Gastroenterol. 2017;23(13):2337–455. https://doi.org/10.3748/wjg.v23.i13.2337.CrossRefPubMedPubMedCentral

62.

Yoo CH, Noh SH. The serum assay of soluble CD44 standard, CD44 variant 5, and CD44 variant 6 in patients with gastric cancer. Cancer Res Treat. 2003;35(1):3–8. https://doi.org/10.4143/crt.2003.35.1.3.CrossRefPubMed

63.

Yang Z, Luo H, Cao Z, Chen Y, Gao J, Li Y, et al. Dual-targeting hybrid nanoparticles for the delivery of SN38 to Her2 and CD44 overexpressed human gastric cancer. Nanoscale. 2016;8(22):11543–58. https://doi.org/10.1039/c6nr01749e.CrossRefPubMed

64.

Yang F, Zheng Z, Xue X, Zheng L, Qin J, Li H, et al. Targeted eradication of gastric cancer stem cells by CD44 targeting USP22 small interfering RNA-loaded nanoliposomes. Future Oncol. 2019;15(3):281–95. https://doi.org/10.2217/fon-2018-0295.CrossRefPubMed

65.

Yamakawa Y, Kusuhara M, Terashima M, Kinugasa Y, Sugino T, Abe M, et al. CD44 variant 9 expression as a predictor for gastric cancer recurrence: immunohistochemical and metabolomic analysis of surgically resected tissues. Biomed Res. 2017;38(1):41–52. https://doi.org/10.2220/biomedres.38.41.CrossRefPubMed

Title: Identification of novel biomarkers, MUC5AC, MUC1, KRT7, GAPDH, CD44 for gastric cancer
Author: Jie Yang
Publication date: 01-05-2020
Publisher: Springer US
Keywords: Gastric Cancer
Gastric Cancer
Biomarkers
Published in: Medical Oncology / Issue 5/2020
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-020-01362-0

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2020

Myths and facts about artificial intelligence: why machine- and deep-learning will not replace interventional radiologists

MRI-guided vacuum-assisted breast biopsy: experience of a single tertiary referral cancer centre and prospects for the future

Delta-radiomics increases multicentre reproducibility: a phantom study

RFA of primary and metastatic lung tumors: long-term results

HR-HPV viral load quality detection provide more accurate prediction for residual lesions after treatment: a prospective cohort study in patients with high-grade squamous lesions or worse

Circular RNAs and their participation in stemness of cancer

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage